Retatrutide, a new dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) binding site , is demonstrating promising data in preliminary human trials . Current inquiry https://socialbuzzfeed.com/story6913292/retatrutide-emerging-research-and-projected-medical-applications